Interstitial pneumonitis in a patient treated with α-interferon and ribavirin for hepatitis C infection

American Journal of the Medical Sciences

Volumn 322, Issue 4, 2001, Pages 233-235

  Karim, Anita ^a,b   Ahmed, Shahid ^a,b   Khan, Arfa ^a,b   Steinberg, Harry ^a,b   Mattana, Joseph ^a,b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Hepatitis C infection; Interferon ; Interstitial pneumonitis; Ribavirin

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; COUGHING; DEPRESSION; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; INTERSTITIAL PNEUMONIA; MALE; MYALGIA; RASH;

EID: 0034755436     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200110000-00015     Document Type: Article

References (19)

1. The interferon system in acute and chronic viral hepatitis
2. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
3. Interferon for non-A, non-B chronic hepatitis: A meta-analysis of randomized clinical trials
4. Interferon alfa-2b monotherapy versus interferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C: Result of a U.S. multicenter randomized controlled study
5. Randomised, double-blind, placebo-controlled trial of interferon-α2b with and without ribavirin for chronic hepatitis C
6. Side effects of alpha interferon in chronic hepatitis C
7. Pneumonitis associated with natural and recombinant interferon alphatherapy for chronic hepatitis C
8. Side effects of high-dose interferon therapy for chronic hepatitis C
9. Classification of chronic hepatitis: Diagnosis, grading and staging
10. Panel statement: Management of hepatitis C
11. Epidemiology of hepatitis C
12. Liver transplantation for chronic viral hepatitis
13. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
14. Effect of intermittent interferon (IFN), daily IFN and IFN plus ribavirin induction therapy on hepatitis C virus genotype 1b replication kinetics and clearance
15. Effector mechanisms of immune responses
16. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy
17. Interferons and autoimmunity
18. Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1, and procoagulant activity and preserves TH1 cytokine production, but inhibits TH2 cytokine response
19. Combination treatment with interferon and ribavirin for chronic hepatitis C